Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.15.0375 on May 27 2008

Journal of Clinical Oncology, Vol 26, No 21 (July 20), 2008: pp. 3543-3551
© 2008 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scagliotti, G. V.
Right arrow Articles by Gandara, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scagliotti, G. V.
Right arrow Articles by Gandara, D.
Related Articles
Right arrowRelated Article
Right arrowRelated Editorial
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Goksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David Gandara

From the University of Torino, Orbassano; San Camillo-Forlanini Hospitals, Rome, Italy; Tata Memorial Hospital, Mumbai; Nizam's Institute of Medical Sciences, Hyderabad; Bangalore Institute of Oncology, Bangalore, India; Asklepios-Fachkliniken Munchen, Gauting; Heidelberg University Medical Center, Mannheim; Hospital Grosshansdorf, Grosshansdorf, Germany; Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, the Netherlands; University Hospital Gasthuisberg, Leuven, Belgium; Specjalistyczny Szpital Im, Szczecin; Maria Sklodowska-Curie Memorial Institute, Krakow, Poland; National Cancer Institute-Brazil, Rio de Janeiro, Brazil; National Cancer Center, Goyang; Samsung Medical Center, Seoul, South Korea; Herlev University Hospital, Herlev, Denmark; Ege University, Izmir, Turkey; Eli Lilly & Co, Canada, Toronto, Ontario Canada; Eli Lilly & Co, Indianapolis, IN; University of California Davis Cancer Center, Sacramento, CA

Corresponding author: Giorgio Vittorio Scagliotti, MD, University of Torino, Department of Clinical and Biological Sciences, S. Luigi Hospital, Regione Gonzole, 10, Orbassano (Torino), Italy 10043; e-mail: giorgio.scagliotti{at}unito.it

Purpose Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting.

Patients and Methods This noninferiority, phase III, randomized study compared the overall survival between treatment arms using a fixed margin method (hazard ratio [HR] < 1.176) in 1,725 chemotherapy-naive patients with stage IIIB or IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 1. Patients received cisplatin 75 mg/m2 on day 1 and gemcitabine 1,250 mg/m2 on days 1 and 8 (n = 863) or cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on day 1 (n = 862) every 3 weeks for up to six cycles.

Results Overall survival for cisplatin/pemetrexed was noninferior to cisplatin/gemcitabine (median survival, 10.3 v 10.3 months, respectively; HR = 0.94; 95% CI, 0.84 to 1.05). Overall survival was statistically superior for cisplatin/pemetrexed versus cisplatin/gemcitabine in patients with adenocarcinoma (n = 847; 12.6 v 10.9 months, respectively) and large-cell carcinoma histology (n = 153; 10.4 v 6.7 months, respectively). In contrast, in patients with squamous cell histology, there was a significant improvement in survival with cisplatin/gemcitabine versus cisplatin/pemetrexed (n = 473; 10.8 v 9.4 months, respectively). For cisplatin/pemetrexed, rates of grade 3 or 4 neutropenia, anemia, and thrombocytopenia (P ≤ .001); febrile neutropenia (P = .002); and alopecia (P < .001) were significantly lower, whereas grade 3 or 4 nausea (P = .004) was more common.

Conclusion In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine. This is the first prospective phase III study in NSCLC to show survival differences based on histologic type.

published online ahead of print at www.jco.org on May 27, 2008.

Supported by Eli Lilly & Co, Indianapolis, IN.

Presented at the 12th World Conference on Lung Cancer, September 1-6, 2007, Seoul, South Korea; and the 14th European Cancer Conference, September 23-26, 2007, Barcelona, Spain.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on www.JCO.org.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
    Jean-Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti, Jean-Yves Douillard, Frances A. Shepherd, Richard J. Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour, Stephen G. Spiro, Estelle Rolland, Roldano Fossati, Delphine Aubert, Keyue Ding, David Waller, and Thierry Le Chevalier
    JCO 2008 26: 3552-3559 [Abstract] [Full Text]

Related Editorial

  • First-Line Chemotherapy for Non–Small-Cell Lung Cancer: Is There a Superior Regimen Based on Histology?
    Lawrence H. Einhorn
    JCO 2008 26: 3485-3486 [Full Text]

Related Correspondence

  • Personalized Medicine in Advanced Non–Small-Cell Lung Cancer: Reality or Wishful Thinking?
    Filip Janku and Brian Bird
    JCO 2008 26: 5651 [Full Text]


This article has been cited by other articles:


Home page
 JCOHome page
S. M. Lee, R. Rudd, P. J. Woll, C. Ottensmeier, D. Gilligan, A. Price, S. Spiro, N. Gower, M. Jitlal, and A. Hackshaw
Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 1, 2009; 27(31): 5248 - 5254.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. S.K. Mok, Y.-L. Wu, C.-J. Yu, C. Zhou, Y.-M. Chen, L. Zhang, J. Ignacio, M. Liao, V. Srimuninnimit, M. J. Boyer, et al.
Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 20, 2009; 27(30): 5080 - 5087.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. Sorrentino and E. Di Carlo
Expression of IL-32 in Human Lung Cancer Is Related to the Histotype and Metastatic Phenotype
Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 769 - 779.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. N. Syrigos, J. Vansteenkiste, P. Parikh, J. von Pawel, C. Manegold, R. G. Martins, L. Simms, K. P. Sugarman, C. Visseren-Grul, and G. V. Scagliotti
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Ann. Onc., October 14, 2009; (2009) mdp392v1.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. West, D. Harpole, and W. Travis
Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer
Chest, October 1, 2009; 136(4): 1112 - 1118.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski, E. F. Smit, P. Lorigan, K. Konduri, M. Reck, A. Szczesna, J. Blakely, P. Serwatowski, N. A. Karaseva, T. Ciuleanu, et al.
Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer
J. Clin. Oncol., October 1, 2009; 27(28): 4787 - 4792.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Rossi, M. Papotti, M. Barbareschi, P. Graziano, and G. Pelosi
Morphology and a Limited Number of Immunohistochemical Markers May Efficiently Subtype Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 1, 2009; 27(28): e141 - e142.
[Full Text] [PDF]

Home page
 Anticancer ResHome page
E. M. KARAPANAGIOTOU, P. G. BOURA, G. PAPAMICHALIS, M. KONSTANTINOU, E. SEPSAS, G. CHAMALAKIS, P. SIMSIRIS, I. GKIOZOS, and K. N. SYRIGOS
Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Res, October 1, 2009; 29(10): 4297 - 4301.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Horn and W. Pao
EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 10, 2009; 27(26): 4232 - 4235.
[Full Text] [PDF]

Home page
 ChestHome page
W. N. William Jr, H. Y. Lin, J. J. Lee, S. M. Lippman, J. A. Roth, and E. S. Kim
Revisiting Stage IIIB and IV Non-small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology, and End Results Data
Chest, September 1, 2009; 136(3): 701 - 709.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bennouna, H. Senellart, and J.-Y. Douillard
Non-small-cell lung cancer: should histology guide chemotherapy treatment?
Ann. Onc., September 1, 2009; 20(9): 1608 - 1609.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Pao, M. G. Kris, A. J. Iafrate, M. Ladanyi, P. A. Janne, I. I. Wistuba, R. Miake-Lye, R. S. Herbst, D. P. Carbone, B. E. Johnson, et al.
Integration of Molecular Profiling into the Lung Cancer Clinic
Clin. Cancer Res., September 1, 2009; 15(17): 5317 - 5322.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. H. Cohen, R. Justice, and R. Pazdur
Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
Oncologist, September 1, 2009; 14(9): 930 - 935.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. H. Schiller, T. Larson, S.-H. I. Ou, S. Limentani, A. Sandler, E. Vokes, S. Kim, K. Liau, P. Bycott, A. J. Olszanski, et al.
Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
J. Clin. Oncol., August 10, 2009; 27(23): 3836 - 3841.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Patel, T. A. Hensing, A. Rademaker, E. M. Hart, M. G. Blum, D. T. Milton, and P. D. Bonomi
Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 10, 2009; 27(20): 3284 - 3289.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Y. Soon, M. R. Stockler, L. M. Askie, and M. J. Boyer
Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
J. Clin. Oncol., July 10, 2009; 27(20): 3277 - 3283.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski
Re-Evaluating Duration of Therapy in Advanced Non-Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure?
J. Clin. Oncol., July 10, 2009; 27(20): 3268 - 3270.
[Full Text] [PDF]

Home page
 JCOHome page
B. H. Gronberg, R. M. Bremnes, O. Flotten, T. Amundsen, P. Fr. Brunsvig, H. H. Hjelde, S. Kaasa, C. von Plessen, F. Stornes, T. Tollali, et al.
Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2009; 27(19): 3217 - 3224.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. H. Tan, J. Rolski, T. Grodzki, C. P. Schneider, U. Gatzemeier, P. Zatloukal, E. Aitini, G. Carteni, H. Riska, Y. H. Tsai, et al.
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
Ann. Onc., July 1, 2009; 20(7): 1249 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. Bhargava
VEGF kinase inhibitors: how do they cause hypertension?
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2009; 297(1): R1 - R5.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. C. Racanelli, S. B. Rothbart, C. L. Heyer, and R. G. Moran
Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition
Cancer Res., July 1, 2009; 69(13): 5467 - 5474.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
G. Rossi, G. Pelosi, P. Graziano, M. Barbareschi, and M. Papotti
Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non--Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments
International Journal of Surgical Pathology, June 1, 2009; 17(3): 206 - 218.
[Abstract] [PDF]

Home page
 JCOHome page
D. D. Karp, L. G. Paz-Ares, S. Novello, P. Haluska, L. Garland, F. Cardenal, L. J. Blakely, P. D. Eisenberg, C. J. Langer, G. Blumenschein Jr, et al.
Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 20, 2009; 27(15): 2516 - 2522.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Dubey and C. A. Powell
Update in Lung Cancer 2008
Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 860 - 868.
[Full Text] [PDF]

Home page
 Ann OncolHome page
H. L. West, H. A. Wakelee, M. C. Perry, R. J. Belt, R. Chen, and C. Obasaju
Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
Ann. Onc., May 1, 2009; 20(5): 850 - 856.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Bono and H. Joensuu
Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
Ann. Onc., May 1, 2009; 20(5): 967 - 967.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
T. E. Stinchcombe and M. A. Socinski
Current Treatments for Advanced Stage Non-Small Cell Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 233 - 241.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Scagliotti, N. Hanna, F. Fossella, K. Sugarman, J. Blatter, P. Peterson, L. Simms, and F. A. Shepherd
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Oncologist, March 1, 2009; 14(3): 253 - 263.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli, P. Maione, A. Rossi, M. L. Ferrara, M. A. Bareschino, C. Schettino, P. C. Sacco, and F. Ciardiello
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
Oncologist, February 1, 2009; 14(2): 137 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J.-M. Sun, K.-W. Lee, J. H. Kim, Y. J. Kim, H. I. Yoon, J.-H. Lee, C.-T. Lee, and J. S. Lee
Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 27 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. J. Dickgreber, T. H. Fink, J. E. Latz, A. M. Hossain, L. C. Musib, and M. Thomas
Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer
Clin. Cancer Res., January 1, 2009; 15(1): 382 - 389.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Janku and B. Bird
Personalized Medicine in Advanced Non-Small-Cell Lung Cancer: Reality or Wishful Thinking?
J. Clin. Oncol., December 1, 2008; 26(34): 5651 - 5651.
[Full Text] [PDF]

Home page
 JCOHome page
G. V. Scagliotti and K. P. Sugarman
In Reply
J. Clin. Oncol., December 1, 2008; 26(34): 5651 - 5652.
[Full Text] [PDF]

Home page
 JCOHome page
L. H. Einhorn
First-Line Chemotherapy for Non-Small-Cell Lung Cancer: Is There a Superior Regimen Based on Histology?
J. Clin. Oncol., July 20, 2008; 26(21): 3485 - 3486.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online